Evrysdi (Risdiplam) Patent Expiration, LOE Window & CMS Spending

Evrysdi (Risdiplam) by Roche / Genentech: FDA Orange Book core substance LOE 2041-04-15, 0 AB generics, $499.8M 2024 CMS Part D & Medicaid spend, and $33,653 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRoche / Genentech
FDA Application & PathwayN213535 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-04-15
Last Listed Patent or Exclusivity Date2041-04-15
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$499.8M
2024 Medicare Part D Spend$154.5M
2024 Medicaid Spend$345.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($33,653 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.